Hyperlipidemia Clinical Trial
Official title:
Effects of an ad Libitum Consumed Low-fat Plant-based Diet Supplemented With Plant-based Meal Replacements on Variety of Risk Factors for Chronic Non-communicable Diseases
The effect of a diet free from animal-sourced nutrients on a variety of risk factors for
chronic non-communicable diseases in weight reduction programs is not well established. In
this non-randomised interventional study, the investigators will document the effects of a
low-fat, plant-based diet supplemented with two daily plant-based meal replacements on serum
LDL cholesterol as a primary end-point and total cholesterol, triglycerides, serum fasting
glucose, serum urate, serum insulin-like growth factor 1 (IGF-1) and body fat mass as
secondary end-points. These end-points will be measured at baseline, after 10 weeks and after
36 weeks of intervention. Participants will be enrolled in the interventional arm with
prescribed low fat plant-based diet from the group of all applicants to a free living
population-based diet optimising program. The choice to participate in the study will be made
by participants themselves.
The investigators hypothesise that low-fat plant based diet supplemented with plant-based
meal replacements eaten ad libitum allows a significant reduction of serum LDL cholesterol
concentration.
This study is designed as a non-randomized, interventional 36 week trial. The dietary
intervention is executed in free living conditions with participants engaging in their
regular daily work and social activities.
The dietary intervention was executed in free-living conditions with participants engaging in
their regular daily work and social activities. The plant-based dietary plan included 2
plant-based meal replacement and 3 conventional meals based on starch nutrients (potatoes,
sweet potatoes, rice, oatmeal, whole-grain pasta, beans, peas, lentils, and similar ones),
fruits (seasonal fruits and various berries), and nonstarch vegetables (color and leafy
vegetables). Spices and tomato sauce (without oil) and one regular-sized spoon of flaxseed
were recommended as well. The participants were recommended to consume no more than 5-6 grams
of salt per day. All milk and dairy products, vegetable oils, and fats were excluded from the
diet. Meat was allowed (but not recommended) once weekly to relieve social pressures on
participants which they often encountered from their circle of influence (i.e., family,
friends, and coworkers) when changing the diet to plant-based sources. The total
macronutrient composition of the intervention diet was approximated to 15% protein, 70%
carbohydrates, and 15% fat. No soybean was included in first 10 weeks of intervention.
Dietary fiber content was approximated to 40-45 g per day. Both meal replacements and
conventional meals were allowed to be consumed ad libitum (to full satiety). No calorie count
or limits were instituted. Additionally, two herbal drinks daily containing black, green and
hibiscus tea extracts were added to the intervention.
After 10 weeks, we have added to the interventional diet EPA and DHA omega 3 fatty acids
(once per day 3 tbl or 567 mg per 1 tbl), vitamin B12 - methylcobalamin (1000 mcg twice a
week) and additional intake of dietary fiber supplement powder (three times a day of 5 g) on
supplement side and a larger selection of moderate amount of high fat whole plant-based foods
(e.g. avocado, soybean tofu, sesame seeds, almonds) at the conventional side.
No calorie count or limits are instituted to test the hypothesis that ad libitum intake of
interventional diet allows significant body fat reduction and improvement variety of risk
factors for chronic non-communicable diseases.
All participants will be followed at weekly intervals for body composition indices and at 10
and 36 weeks for serum biochemical end-points.
Evaluation of dietary diaries and meal photographs will be used to correct and adjust
deviations from the targeted dietary plan and to help participants prepare the meals
according to the dietary plan.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Completed |
NCT02927184 -
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT04640012 -
Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03213288 -
Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status
|
N/A | |
Completed |
NCT00382564 -
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
|
N/A | |
Recruiting |
NCT02979704 -
A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia
|
Phase 2/Phase 3 | |
Completed |
NCT02569814 -
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
|
Phase 1 | |
Completed |
NCT02280590 -
Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia
|
Phase 4 | |
Completed |
NCT02428998 -
Safety for 24 Weeks Intake of Korean Red Ginseng in Adults
|
N/A | |
Completed |
NCT01678183 -
Financial Incentives for Medication Adherence
|
N/A | |
Completed |
NCT01694446 -
Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose
|
N/A | |
Completed |
NCT01426412 -
A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol
|
Phase 1 | |
Completed |
NCT01131832 -
Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols
|
Phase 4 | |
Completed |
NCT00534105 -
Lipid Metabolism in Gestational Diabetes
|
N/A | |
Completed |
NCT00758303 -
A Study to Evaluate the Lipid Regulating Effects of TRIA-662
|
Phase 2/Phase 3 | |
Recruiting |
NCT00408824 -
Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)
|
N/A | |
Terminated |
NCT00299169 -
Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes
|
Phase 4 | |
Completed |
NCT00362206 -
Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
|
Phase 3 | |
Completed |
NCT00414986 -
Using Learning Teams for Reflective Adaptation for Diabetes and Depression
|
N/A | |
Completed |
NCT00701454 -
Survey of Thai-Muslim Health Status
|
N/A |